期刊文献+

骨肉瘤中Bcl-2、Fas蛋白表达的相关性研究 被引量:3

下载PDF
导出
摘要 【目的】研究细胞凋亡的两个调控因子Bcl-2和Fas蛋白在骨肉瘤中的不同表达情况,了解它们在骨肉瘤细胞中的相互关系。【方法】采用SABC免疫组织化学方法检测42例骨肉瘤中Bcl-2、Fas蛋白的染色强度评分,并进行相关分析。【结果】Bcl-2蛋白的染色强度评分为(1.18±0.45);Fas蛋白的染色强度评分为(0.93±0.17);Bcl-2和Fas蛋白在不同病理类型组骨肉瘤中的染色强度评分的差异均无显著性(均P>0.05);Bcl-2与Fas蛋白的染色强度评分之间呈负相关(r=-0.272,P<0.05)。【结论】Bcl-2可能通过抑制Fas蛋白的表达来引起骨肉瘤的发生。
出处 《医学临床研究》 CAS 2006年第4期581-582,共2页 Journal of Clinical Research
  • 相关文献

参考文献12

  • 1Williams GT.Programmed cell death:apoptosis and oncogenesis[J].Cell,1991,65(7):1097-1098.
  • 2王东,陈俐,李增鹏,牟江洪,高奉浔.骨肉瘤细胞凋亡和增殖与预后的关系[J].临床与实验病理学杂志,1999,15(4):312-314. 被引量:8
  • 3Bresalier RS,Ho SB,Schoeppner HI,et al.Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis[J].Gastroenterology,1996,110(5):1354-1367.
  • 4Kerr JFR,Winterford CM,Harmon BV.Apoptosis:its significance in cancer and cancer therapy[J].Cancer,1994,73(8):2013-2026.
  • 5贾克明.加强Fas和Fas配体的研究[J].中华内科杂志,1997,36(10):651-652. 被引量:9
  • 6Suda T,Takahashi T,Golstein P,et al.Molecular cloning and expression of the Fas Ligand,a novel member of the tumor necrosis factor family[J].Cell,1993,75(6):1169-1178.
  • 7Chen-Levy Z,Cleary ML.Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro[J].J Biol Chem,1990,265(9):4929-4933.
  • 8Columban A,Ledda-columbano GM,Rao PM,et al.Occurrence of cell death (apoptosis) in preneoplastic and neoplastic liver cells[J].Am J Pathol,1984,116(3):441-446.
  • 9Vaux DI.Bcl-2 genes promotes heamopoietic cells survival and cooperates with c-myc to immortalize pre-B-cells[J].Nature,1988,335(6189):440-442.
  • 10Carson DA,Ribeiro JM.Apoptosis and disease[J].Lancet,1993,341(8855):1251-1254.

二级参考文献4

共引文献18

同被引文献40

  • 1刘国辉,杨述华,郜勇,郭晓东.凋亡相关基因Survivin mRNA在骨肉瘤中表达的测定及其意义[J].中华实验外科杂志,2004,21(7):863-865. 被引量:2
  • 2许凌峰,王远成,俞炜源.Bcl-2蛋白的研究进展[J].生物技术通讯,2005,16(4):429-431. 被引量:7
  • 3郑定容,黄龙,杨庆珣.HBV、HCV感染与HCC发生的关系[J].中国热带医学,2006,6(1):73-73. 被引量:3
  • 4高天,郭乔楠.人骨肉瘤中bc1_2的表达与凋亡指数的关系及其临床意义[J].诊断病理学杂志,2006,13(5):365-367. 被引量:4
  • 5Hurwitz H,Fehrenbacher L,Novomy W,et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350: 2335-2342.
  • 6Johnson DH, Fehrenbacher L, NovotnyWF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J]. J Clin Oncol, 2004, 22:2184-2191.
  • 7Xiong YQ, Sun HC, Zhu XDJ, et al. Bevacizumab enhances chemos- ensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression [J]. Cancer Res Clin Oncol, 2011,137(3): 505-512.
  • 8G. Klement, S. Baruchel, J. Rak, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity[J]. J. Clin. Invest, 2000, 105 : 15-R24.
  • 9Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer[J]. Nat Clin Pract Oncol, 2006, 3:24-40.
  • 10Satoh H, Ishikawa H, Fujimoto M, et al. Combined effects of TNP-470 and paclitaxel in human non-small cell lung cancer cell lines[J]. Anticancer Res,1998,18:1027-1030.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部